Sarepta Therapeutics (SRPT) Common Equity (2010 - 2026)

Sarepta Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Common Equity rose 31.71% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 31.71% YoY), while the FY2025 annual figure was $1.1 billion, down 25.34% from the prior year.
• Common Equity for Q1 2026 stood at $1.5 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Common Equity was $1.5 billion in Q4 2024, with the low at $385.0 million in Q4 2022.
• The 5-year median for Common Equity is $961.2 million (2024), against an average of $984.1 million.
• The sharpest annual moves came in 2022 and 2023: Common Equity plunged 58.52% in 2022, then jumped 123.23% in 2023.
• Sarepta Therapeutics' Common Equity stood at $385.0 million in 2022, then jumped by 123.23% to $859.3 million in 2023, then surged by 77.78% to $1.5 billion in 2024, then fell by 25.34% to $1.1 billion in 2025, then soared by 31.95% to $1.5 billion in 2026.
• Business Quant data shows SRPT's Common Equity at $1.5 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.